LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Acadia investigation page on our website at www.glancylaw.com/case/acadia-healthcare-company-inc.
On October 24, 2017, Acadia reported disappointing Q3 2017 results. Revenue for the quarter was only $716.7 million, a decrease compared to $734.7 million for the third quarter of 2016. The Company attributed the results, in part, to “lower census and higher operating costs than anticipated” in the United Kingdom. Acadia also reduced revenue guidance for fiscal year 2017 from “a range of $2.85 billion to $2.9 billion” to “a range of $2.82 billion to $2.83 billion.”
On this news, Acadia’s share price fell $11.44, or 25.9%, to close at $32.68 per share on October 25, 2017, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Acadia securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.